Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission

Annals of Neurology

Volumn 31, Issue 4, 1992, Pages 366-373

  Calabresi, Paolo ^a   De Murtas, Marco ^a   Mercuri, Nicola Biagio ^a   Bernardi, Giorgio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; GLUTAMATE RECEPTOR; GLUTAMIC ACID; HALOPERIDOL; POSTSYNAPTIC RECEPTOR; PRESYNAPTIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; NONHUMAN; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RAT; RECEPTOR SENSITIVITY; SYNAPTIC POTENTIAL;

AGING; ANIMAL; ANTIPSYCHOTIC AGENTS; CORPUS STRIATUM; ERGOLINES; GLUTAMINE; HALOPERIDOL; PARASYMPATHOMIMETICS; QUINPIROLE; RATS; RATS, INBRED STRAINS; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; RECEPTORS, GABA-A; RECEPTORS, MUSCARINIC; SUPPORT, NON-U.S. GOV'T; SYNAPTIC TRANSMISSION; TIME FACTORS;

EID: 0026689231     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.410310404     Document Type: Article

References (50)

1. Drug treatment of acute schizophrenia
2. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
3. Dopamine, GABA, cholecystokinin and opioids in neuroleptic‐induced tardive dyskinesia
4. Tardive dyskinesia
5. Is the dopamine hypothesis of tardive dyskinesia completely wrong?
6. Brain dopamine receptors
7. Dopaminergic supersensitivity induced by denervation and chronic receptor blockade is additive
8. Dopamine receptors in the denervated striatum: further supersensitivity by chronic haloperidol treatment
9. Chronic treatment with SCH 23390 and haloperidol: effects on dopaminergic and serotoninergic mechanisms in rat brain
10. Effects of long‐term haloperidol treatment on the responsiveness of accumbens neurons to cholecystokinin and dopamine: electrophysiological and radioligand binding studies in the rat
11. Neurobiological substrates of tardive dyskinesia: the GABA hypothesis
12. Association with persistent neuroleptic‐induced dyskinesia of regional changes in brain GABA synthesis
13. Brain γ‐aminobutyric acid abnormality in tardive dyskinesia
14. A theory of the functional organization of the neostriatum and the neostriatal control of voluntary movement
15. 2‐receptors: their implications in dopamine‐substitute therapy for Parkinson's disease
16. Antagonism of cortical excitation of striatal neurons by glutamic acid diethyl ester: evidence for glutamic acid as an excitatory transmitter in the rat striatum
17. High affinity uptake of glutamate in terminals of corticostriatal axons
18. Glutamate release in vitro from corticostriatal terminals
19. Duplication of biochemical changes of Huntigton's chorea by intrastriatal injections of glutamic acid and kainic acid
20. 3H] glutamate binding in Alzheimer's and Huntington's diseases
21. NMDA receptor losses in putamen from patients with Huntington's disease
22. Dopamine receptors: pharmacological and anatomical evidences indicate that two distinct populations are present in rat striatum
23. Dopamine receptors localized on cerebral cortical afferents to rat corpus striatum
24. 3H] sulpiride binding in rats, so D‐2 receptors exist postsynaptically on cortico‐striate afferents and striatal neurons
25. Release‐regulating D‐2 dopamine receptors are located on striatal glutamatergic nerve terminals
26. Intrinsic membrane properties of neostriatal neurons can account for their low level of spontaneous activity
27. Intracellular studies on the dopamine‐induced firing inhibition of neostriatal neurons in vitro: evidence for D1 receptor involvement
28. Depletion of catecholamines reveals inhibitory effects of bromocriptine and lysuride on neostriatal neurones recorded intracellularly in vitro
29. Endogenous dopamine and dopaminergic agonists modulate synaptic excitation in neostriatum: intracellular studies from native and catecholamine‐depleted rats
30. Synaptic and intrinsic control of membrane excitability of neostriatal neurons. II. An in vitro analysis
31. Endogenous GABA mediates presynaptic inhibition of spontaneous and evoked excitatory synaptic potentials in the rat neostriatum
32. Kainic acid on neostriatal neurons intracellularly recorded in vitro: electrophysiological evidence for differential neuronal sensitivity
33. The striatal cholinergic interneuron: synaptic target of dopaminergic terminals
34. Aging process affects a single class of dopamine receptors
35. Dopaminergic changes in the basal ganglia: a generalized phenomenon of aging in mammals
36. Effects of age on dopamine and serotonin receptors measured by positron emission tomography in the living human brain
37. Involvement of GABA systems in the feed‐back regulation of glutamate and GABA‐mediated synaptic potentials in the rat neostriatum
38. Muscarinic modulation in the neostriatum: possible involvement of calcium
39. Morphological and physiological properties of neostriatal neurons: an intracellular horseradish peroxidase study in the rat
40. Identification of projecting neurons in rat neostriatal slices
41. Localization of D‐2 dopamine receptors to intrinsic striatal neurones by quantitative autoradiography
42. 2 sites in rat caudate‐putamen: localization to intrinsic neurons and not neocortical afferents
43. 2 receptor binding in the rat brain and pituitary: an in situ hybridization‐receptor autoradiographic analysis
44. 2 dopamine receptor mRNA in rat brain
45. 2 receptor in the rat brain by in situ hybridization histochemistry
46. 2 dopamine receptors in the medial preforontal cortex of the rat
47. 3H‐YM‐09151‐2 binding sites in rat frontal cortex and the effects of subchronic treatment with haloperidol on cortical D‐2 dopamine receptors
48. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain
49. 3H‐flunitrazepam binding during continuous treatment of rats for up to 1 year with haloperidol, sulpiride and clozapine
50. 2 dopamine receptor‐regulated gene expression of striatonigral and striatopallidal neurons